Email updates

Keep up to date with the latest news and content from Dynamic Medicine and BioMed Central.

Open Access Research

The Economic impact of ME/CFS: Individual and societal costs

Leonard A Jason1*, Mary C Benton2, Lisa Valentine3, Abra Johnson1 and Susan Torres-Harding4

Author Affiliations

1 Department of Psychology, Depaul University, Center for Community Research, Chicago, IL, USA

2 Department of Psychology, Wichita State University, Wichita, KS, USA

3 Department of Psychology, University of North Texas, Denton, TX, USA

4 Department of Psychology, Roosevelt University, Chicago, IL, USA

For all author emails, please log on.

Dynamic Medicine 2008, 7:6  doi:10.1186/1476-5918-7-6

Published: 8 April 2008

Abstract

Background

ME/CFS is characterized by debilitating fatigue in addition to other physical and cognitive symptoms. It is estimated to affect over 800,000 adults in the U.S. ME/CFS often results in diminished functionality and increased economic impact. The economic impact of an illness is generally divided into two categories: direct and indirect costs. Despite high prevalence rates and the disabling nature of the illness, few studies have examined the costs of ME/CFS at the individual and societal level. In fact, of the four studies examining the economic impact of ME/ME/CFS only two used a U. S. sample. The current study used community and tertiary samples to examine the direct costs of ME/CFS.

Methods

Using archival data, Study 1 examined the direct cost of ME/CFS in a community-based sample in Chicago. Study 2 estimated the direct cost of ME/CFS in a tertiary sample in Chicago. Both Study1 and Study 2 assessed direct costs using office visit costs, medical test costs, and medication costs.

Results

For Study 1, the annual direct total cost per ME/CFS patient was estimated to be $2,342, with the total annual direct cost of ME/CFS to society being approximately $2 billion. In Study 2, the annual direct was estimated to be $8,675 per ME/CFS patient, with the total annual direct cost of ME/CFS to society being approximately $7 billion.

Conclusion

Using ME/CFS prevalence data of 0.42 and indirect costs estimates from Reynolds et al. (2004), the direct and indirect cost of ME/CFS to society was estimated to be $18,677,912,000 for the community sample and $23,972,300,000 for the tertiary sample. These findings indicate that whether or not individuals are recruited from a community or tertiary sample, ME/CFS imposes substantial economic costs.